Gilenya Generics May Be Imminent Amid US Federal Circuit Snub
HEC May Face US Supreme Court Date As Novartis Loses Again
Are US Gilenya generics set to flood the US market? HEC Pharm is hoping so, following a favorable Federal Circuit denial. However, in a bid to maintain its monopoly and avoid a potential $300m hit to its top line, Novartis is taking its fight to the US Supreme Court.
